Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Rating of "Hold" by Analysts

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have earned an average rating of "Hold" from the nine brokerages that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $11.75.

Several research firms have issued reports on INZY. Wedbush cut shares of Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Inozyme Pharma in a research note on Thursday, April 10th. Jefferies Financial Group reissued a "hold" rating and issued a $4.00 price target (down previously from $15.00) on shares of Inozyme Pharma in a research note on Friday, May 16th. TD Cowen lowered shares of Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th. Finally, Piper Sandler dropped their price objective on shares of Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th.

Inozyme Pharma Stock Performance

Shares of NASDAQ:INZY traded up $0.01 during midday trading on Monday, reaching $3.98. 302,728 shares of the company traded hands, compared to its average volume of 881,549. The firm's fifty day moving average price is $2.18 and its two-hundred day moving average price is $1.93. The firm has a market capitalization of $256.96 million, a price-to-earnings ratio of -2.55 and a beta of 2.29. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a 12 month low of $0.72 and a 12 month high of $6.24.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). On average, equities analysts expect that Inozyme Pharma will post -1.59 earnings per share for the current year.

Hedge Funds Weigh In On Inozyme Pharma

A number of large investors have recently added to or reduced their stakes in INZY. Harvest Investment Services LLC purchased a new position in shares of Inozyme Pharma in the fourth quarter worth about $31,000. Graham Capital Management L.P. bought a new position in Inozyme Pharma during the 4th quarter worth approximately $33,000. 49 Wealth Management LLC purchased a new position in Inozyme Pharma in the 1st quarter worth approximately $38,000. D. E. Shaw & Co. Inc. bought a new stake in Inozyme Pharma in the fourth quarter valued at approximately $49,000. Finally, ProShare Advisors LLC bought a new stake in Inozyme Pharma in the fourth quarter valued at approximately $49,000. Hedge funds and other institutional investors own 88.30% of the company's stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.